A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
MeSH terms: Fallopian Tube Neoplasms; Peritoneal Neoplasms
Intervention: Paclitaxel; Carboplatin; Atezolizumab; Bevacizumab; Atezolizumab Placebo
Intervention description: Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle; Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles; Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle; Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms; Placebo matching to atezolizumab on Day 1 of each 21-day cycle
Intervention MeSH terms: Paclitaxel; Bevacizumab; Carboplatin; Atezolizumab; Antibodies, Monoclonal
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 1301.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the
      efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo +
      paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian
      cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic
      residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will
      undergo neoadjuvant therapy followed by interval surgery.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC),
             peritoneal primary carcinoma, or fallopian tube cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Life expectancy greater than (>) 12 weeks

          -  For participants who receive therapeutic anticoagulation: stable anticoagulant regimen

          -  Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
             specimen in paraffin blocks (preferred) or at least 20 unstained slides (for detailed
             tissue requirements at screening)

        Exclusion Criteria:

          -  Received a current diagnosis of borderline epithelial ovarian tumor (formerly tumors
             of low malignant potential)

          -  Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal
             cancer that was treated only with surgery (example [e.g.], participants with Stage IA
             or Stage IB epithelial ovarian or fallopian tube cancers)

          -  Have non-epithelial ovarian tumors (e.g., germ cell tumors, sex cord stromal tumors)

          -  Received prior radiotherapy to any portion of the abdominal cavity or pelvis

          -  Received prior chemotherapy for any abdominal or pelvic tumor that include neoadjuvant
             chemotherapy (NACT) for ovarian, primary peritoneal or fallopian tube cancer

          -  Received any biological and/or targeted therapy (including but not limited to
             vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management
             and/or treatment of epithelial ovarian or peritoneal primary cancer

          -  Have synchronous primary endometrial cancer

          -  Have a prior history of primary endometrial cancer, except: Stage IA cancer;
             superficial myometrial invasion, without lymphovascular invasion; grade less than (<)
             3 or poorly differentiated subtypes, and this includes papillary serous, clear cell or
             other International Federation of Gynecological Oncologists (FIGO) Grade 3 lesions

          -  With the exception of non-melanoma skin cancer and other specific malignancies as
             noted above, other invasive malignancies with any evidence of other cancers present
             within the last 5 years or previous cancer treatment that contraindicates this
             protocol therapy

          -  Have a known hypersensitivity or allergy to biopharmaceutical agents produced in
             Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab
             formulations

          -  Undergo major surgical procedure within 28 days prior to first bevacizumab dose, or
             anticipation of the need for a major surgical procedure during the course of the study
             except participants who receive NACT and will need interval surgery. This may include
             but is not limited to laparotomy.

          -  Have prior allogeneic bone marrow transplantation or solid organ transplant

          -  Have any other diseases, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results

          -  Have any approved or investigational anti-cancer therapy, including chemotherapy or
             hormonal therapy, with exceptions: Hormone-replacement therapy or oral contraceptives

          -  Are administered treatment with any other investigational agent or participation in
             another clinical study with anti-cancer therapeutic intent

          -  Have core biopsy or other minor surgical procedures within 7 days prior to the first
             dose of bevacizumab

          -  Have known sensitivity to any component of bevacizumab

          -  Have known sensitivity to any component of paclitaxel

          -  Current treatment with anti-viral therapy for hepatitis B virus (HBV)

          -  History of leptomeningeal disease